Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib vs placebo vs adalimumab in methotrexate-inadequate response rheumatoid arthritis
2015-003333-95Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in rheumatoid arthritis (RA) (3 arms), sponsored by AbbVie Inc. Primary endpoints: ACR20 response at Week 12 and Clinical remission by DAS28 (CRP) at Week 12. Started Nov 2015; status: active.
02
Drugs
upadacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2015-003333-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003333-95.